Korean J Lab Med.  2009 Jun;29(3):249-255. 10.3343/kjlm.2009.29.3.249.

Comparative Quantification of Plasma hnRNP B1 mRNA in Non-small Cell Lung Cancer Patients by Real-time PCR

• Kim JM
• Hwang SH
• Song EJ
• Lee SY
• Kim YD
• Lee CH
• Lee MK
• Chang CL
• Lee EY

• KMID: 1096978
• DOI: http://doi.org/10.3343/kjlm.2009.29.3.249

Abstract

BACKGROUND: Circulating cell-free nucleic acids are known to be a noninvasive diagnostic tool for cancer detection. Heterogeneous nuclear ribonucleoprotein (hnRNP) B1, a nuclear core complex, is overexpressed in early stage lung cancer. We intended to evaluate the usefulness of plasma hnRNP B1 mRNA in differentiating non-small cell lung cancer (NSCLC) from other benign lung diseases, especially pulmonary tuberculosis, which is highly prevalent in Korea and often difficult to distinguish from lung cancer.
METHODS
Plasma RNA was extracted from 30 patients with NSCLC, 30 patients with benign lung diseases including pulmonary tuberculosis, and 10 healthy controls. Plasma hnRNP B1 mRNA was measured by TaqMan Gene Expression Assay (Applied Biosystems, USA), and pre-developed beta-actin (ACTB) mRNA was used for normalization. We analyzed the relative gene expression data using the delta-delta Ct method.
RESULTS
Plasma hnRPN B1 mRNA was measurable in 93.3% (28/30) of NSCLC patients. Normalized 2-DeltaDeltaCt of plasma hnRPN B1 mRNA was 62.2 (95%Cl, 6.4-210.1) in NSCLC patients and 2.7 (95%Cl, 0.5-13.6) in benign lung disease patients (P<0.001, Mann-Whitney U test).
CONCLUSIONS
Plasma hnRNP B1 mRNA was significantly increased in patients with lung cancer compared with that in patients with other benign lung diseases. Plasma hnRNP B1 mRNA may be useful as a potential marker for the detection of NSCLC.

Keyword

Lung cancer; hnRNP B1; Plasma mRNA; Cancer biomarker; Circulating nucleic acid

MeSH Terms

Adult
Aged
Carcinoma, Non-Small-Cell Lung/*genetics
Female
Heterogeneous-Nuclear Ribonucleoprotein Group A-B/*blood/genetics
Humans
Lung Diseases/blood/genetics
Lung Neoplasms/*genetics
Male
Middle Aged
Polymerase Chain Reaction
RNA, Messenger/*blood/metabolism
Tumor Markers, Biological

Figure

• 

  Fig. 1. (A) Amplified bands (315 bp) were identified on agarose gel electrophoresis after plasma hnRNP B1 mRNA RT-PCR. M, 100 bp ladder; 1-2 lane, normal; 3-5 lane, lung cancer. (B) hnRNP B1 mRNA in the plasma of lung cancer patients was measured by real-time RT-PCR.

• 

  Fig. 2. Normalized plasma hnRNP B1 mRNA in the patient group amount relative to that in normal control group. Fold change was expressed as 2ΔΔCt (ΔCt [hnRNP B1-ACTB] of each case-average ΔCt [average hnRNP B1 Ct-average ACTB Ct] of normal control group).

Reference

1.Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007. 57:43–66.

2.National Cancer Information Center. Cancer incidence. http://www.cancer.go.kr/cms/statics/incidence/index.html. (Updated on Jun. 2008.

3.Melamed MR. Lung cancer screening results in the National Cancer Institute New York study. Cancer. 2000. 89:2356–62.

4.Kopreski MS., Benko FA., Kwak LW., Gocke CD. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin Cancer Res. 1999. 5:1961–5.

5.Zhou J., Mulshine JL., Unsworth EJ., Scott FM., Avis IM., Vos MD, et al. Purification and characterization of a protein that permits early detection of lung cancer. Identification of heterogeneous nuclear ribonucleoprotein-A2/B1 as the antigen for monoclonal antibody 703D4. J Biol Chem. 1996. 271:10760–6.

6.Fleischhacker M., Beinert T., Ermitsch M., Seferi D., Possinger K., Engelmann C, et al. Detection of amplifiable messenger RNA in the serum of patients with lung cancer. Ann N Y Acad Sci. 2001. 945:179–88.

7.Sueoka E., Sueoka N., Iwanaga K., Sato A., Suga K., Hayashi S, et al. Detection of plasma hnRNP B1 mRNA, a new cancer biomarker, in lung cancer patients by quantitative real-time polymerase chain reaction. Lung Cancer. 2005. 48:77–83.

8.Zech VF., Dlaska M., Tzankov A., Hilbe W. Prognostic and diagnostic relevance of hnRNP A2/B1, hnRNP B1 and S100 A2 in non-small cell lung cancer. Cancer Detect Prev. 2006. 30:395–402.

9.Sato A., Sueoka-Aragane N., Saitoh J., Komiya K., Hisatomi T., Tomimasu R, et al. Establishment of a new method, transcription-reverse transcription concerted reaction, for detection of plasma hnRNP B1 mRNA, a biomarker of lung cancer. J Cancer Res Clin Oncol. 2008. 134:1191–7.

10.Mayeda A., Munroe SH., Caceres JF., Krainer AR. Function of conserved domains of hnRNP A1 and other hnRNP A/B proteins. EMBO J. 1994. 13:5483–95.

11.Livak KJ. Comparative Ct Method. ABI PRISM 7700 Sequence Detection System. User Bulletin No. 2. Relative Quantitation of Gene Expression. PE Applied Biosystems. 1997.

12.Leon SA., Shapiro B., Sklaroff DM., Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977. 37:646–50.

13.Sozzi G., Conte D., Mariani L., Lo Vullo S., Roz L., Lombardo C, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 2001. 61:4675–8.

14.Mulcahy HE., Lyautey J., Lederrey C., qi Chen X., Anker P., Alstead EM, et al. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res. 1998. 4:271–5.

15.Andriani F., Conte D., Mastrangelo T., Leon M., Ratcliffe C., Roz L, et al. Detecting lung cancer in plasma with the use of multiple genetic markers. Int J Cancer. 2004. 108:91–6.

16.Esteller M., Sanchez-Cespedes M., Rosell R., Sidransky D., Baylin SB., Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 1999. 59:67–70.

17.Chen XQ., Stroun M., Magnenat JL., Nicod LP., Kurt AM., Lyautey J, et al. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med. 1996. 2:1033–5.

18.Beau-Faller M., Gaub MP., Schneider A., Ducrocq X., Massard G., Gasser B, et al. Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients. Int J Cancer. 2003. 105:361–70.

19.Bremnes RM., Sirera R., Camps C. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer. 2005. 49:1–12.

20.Sozzi G., Conte D., Leon M., Cirincione R., Roz L., Ratcliffe C, et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol. 2003. 21:3902–8.

21.Bruhn N., Beinert T., Oehm C., Jandrig B., Petersen I., Chen XQ, et al. Detection of microsatellite alterations in the DNA isolated from tumor cells and from plasma DNA of patients with lung cancer. Ann NY Acad Sci. 2000. 906:72–82.

22.Soria JC., Rodriguez M., Liu DD., Lee JJ., Hong WK., Mao L. Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Res. 2002. 62:351–5.

23.Sueoka E., Sueoka N., Goto Y., Matsuyama S., Nishimura H., Sato M, et al. Heterogeneous nuclear ribonucleoprotein B1 as early cancer biomarker for occult cancer of human lungs and bronchial dysplasia. Cancer Res. 2001. 61:1896–902.

24.Wu S., Sato M., Endo C., Sakurada A., Dong B., Aikawa H, et al. hnRNP B1 protein may be a possible prognostic factor in squamous cell carcinoma of the lung. Lung Cancer. 2003. 41:179–86.

25.Livak KJ., Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C[T]) Method. Methods. 2001. 25:402–8.

26.Matsuyama S., Goto Y., Sueoka N., Ohkura Y., Tanaka Y., Nakachi K, et al. Heterogeneous nuclear ribonucleoprotein B1 expressed in esophageal squamous cell carcinomas as a new biomarker for diagnosis. Jpn J Cancer Res. 2000. 91:658–63.